Mates Sharon's Insider Trades & SAST Disclosures
Mates Sharon's most recent trade in Intra-Cellular Therapies Inc was a trade of 40,712 Common Stock done . Disclosure was reported to the exchange on March 6, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mates Sharon.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 40,712 | 1,144,646 (1%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 40,712 | 40,713 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 20,566 | 0 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 20,566 | 1,145,364 (1%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 131.19 per share. | 06 Mar 2025 | 19,848 | 1,124,798 (1%) | 0% | 131.2 | 2,603,859 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 131.24 per share. | 06 Mar 2025 | 10,129 | 1,135,235 (1%) | 0% | 131.2 | 1,329,330 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 34,969 | 69,940 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 34,969 | 1,120,912 (1%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 128.20 per share. | 01 Mar 2025 | 16,978 | 1,103,934 (1%) | 0% | 128.2 | 2,176,580 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 121,212 | 121,212 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 30,847 | 1,101,176 (1%) | 0% | 0 | Common Stock | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 127.00 per share. | 31 Jan 2025 | 15,233 | 1,085,943 (1%) | 0% | 127 | 1,934,591 | Common Stock |
| Intra-Cellular Therapies Inc | Mates Sharon | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.73 per share. | 04 Dec 2024 | 51,697 | 1,122,026 (1%) | 0% | 12.7 | 658,103 | Common Stock |
| Intra-Cellular Therapies Inc | Mates Sharon | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2024 | 51,697 | 0 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2024 | 51,000 | 51,697 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.73 per share. | 04 Dec 2024 | 51,000 | 1,121,329 (1%) | 0% | 12.7 | 649,230 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 84.06 per share. | 04 Dec 2024 | 50,163 | 1,071,863 (1%) | 0% | 84.1 | 4,216,928 | Common Stock |
| Intra-Cellular Therapies Inc | Mates Sharon | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 85.62 per share. | 04 Dec 2024 | 27,667 | 1,093,662 (1%) | 0% | 85.6 | 2,368,909 | Common Stock |
| Intra-Cellular Therapies Inc | Mates Sharon | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 86.00 per share. | 04 Dec 2024 | 23,333 | 1,070,329 (1%) | 0% | 86.0 | 2,006,750 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 84.69 per share. | 04 Dec 2024 | 1,534 | 1,070,329 (1%) | 0% | 84.7 | 129,914 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.73 per share. | 29 Aug 2024 | 35,604 | 1,105,933 (1%) | 0% | 12.7 | 453,239 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2024 | 35,604 | 137,093 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.73 per share. | 29 Aug 2024 | 34,396 | 1,104,725 (1%) | 0% | 12.7 | 437,861 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2024 | 34,396 | 102,697 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 72.44 per share. | 29 Aug 2024 | 29,832 | 1,076,101 (1%) | 0% | 72.4 | 2,161,114 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 72.73 per share. | 29 Aug 2024 | 28,203 | 1,076,522 (1%) | 0% | 72.7 | 2,051,261 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 73.32 per share. | 29 Aug 2024 | 6,193 | 1,070,329 (1%) | 0% | 73.3 | 454,091 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 73.25 per share. | 29 Aug 2024 | 5,772 | 1,070,329 (1%) | 0% | 73.2 | 422,771 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 40,513 | 32,699 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.57 per share. | 26 Aug 2024 | 40,513 | 1,110,842 (1%) | 0% | 17.6 | 711,813 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.57 per share. | 26 Aug 2024 | 32,699 | 1,103,028 (1%) | 0% | 17.6 | 574,521 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 32,699 | 0 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 72.74 per share. | 26 Aug 2024 | 32,459 | 1,070,569 (1%) | 0% | 72.7 | 2,361,113 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 73.33 per share. | 26 Aug 2024 | 23,657 | 1,087,185 (1%) | 0% | 73.3 | 1,734,865 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 22,713 | 73,212 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 74.59 per share. | 26 Aug 2024 | 22,713 | 1,070,329 (1%) | 0% | 74.6 | 1,694,229 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.57 per share. | 26 Aug 2024 | 22,713 | 1,093,042 (1%) | 0% | 17.6 | 399,067 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 73.93 per share. | 26 Aug 2024 | 16,856 | 1,070,329 (1%) | 0% | 73.9 | 1,246,191 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 73.70 per share. | 26 Aug 2024 | 240 | 1,070,329 (1%) | 0% | 73.7 | 17,688 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.57 per share. | 21 Aug 2024 | 53,013 | 1,123,342 (1%) | 0% | 17.6 | 931,438 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2024 | 53,013 | 163,985 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 75.40 per share. | 21 Aug 2024 | 44,134 | 1,079,208 (1%) | 0% | 75.4 | 3,327,818 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2024 | 39,380 | 124,605 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.57 per share. | 21 Aug 2024 | 39,380 | 1,109,709 (1%) | 0% | 17.6 | 691,907 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 74.58 per share. | 21 Aug 2024 | 35,011 | 1,074,698 (1%) | 0% | 74.6 | 2,611,075 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2024 | 28,680 | 95,925 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 74.46 per share. | 21 Aug 2024 | 28,680 | 1,070,329 (1%) | 0% | 74.5 | 2,135,435 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.57 per share. | 21 Aug 2024 | 28,680 | 1,099,009 (1%) | 0% | 17.6 | 503,908 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 75.47 per share. | 21 Aug 2024 | 4,369 | 1,070,329 (1%) | 0% | 75.5 | 329,727 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 76.20 per share. | 21 Aug 2024 | 4,297 | 1,074,911 (1%) | 0% | 76.2 | 327,432 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 77.21 per share. | 21 Aug 2024 | 2,682 | 1,072,229 (1%) | 0% | 77.2 | 207,088 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 77.98 per share. | 21 Aug 2024 | 1,900 | 1,070,329 (1%) | 0% | 78.0 | 148,163 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2024 | 11,382 | 216,998 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.57 per share. | 24 Apr 2024 | 11,382 | 1,070,329 (1%) | 0% | 17.6 | 199,982 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.86 per share. | 24 Apr 2024 | 8,638 | 1,058,947 (1%) | 0% | 16.9 | 145,637 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2024 | 8,638 | 0 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 66.38 per share. | 07 Mar 2024 | 31,958 | 1,059,063 (1%) | 0% | 66.4 | 2,121,372 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 20,565 | 1,070,874 (1%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 20,565 | 20,566 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 64.80 per share. | 07 Mar 2024 | 14,541 | 1,056,333 (1%) | 0% | 64.8 | 942,257 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 66.93 per share. | 07 Mar 2024 | 8,754 | 1,050,309 (1%) | 0% | 66.9 | 585,905 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 65.90 per share. | 07 Mar 2024 | 4,128 | 1,052,205 (1%) | 0% | 65.9 | 272,035 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 66.81 per share. | 07 Mar 2024 | 1,590 | 1,050,615 (1%) | 0% | 66.8 | 106,228 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 67.33 per share. | 07 Mar 2024 | 306 | 1,050,309 (1%) | 0% | 67.3 | 20,603 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 40,712 | 81,425 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 40,712 | 1,091,021 (1%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 104,909 | 104,909 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Mates Sharon | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 22,590 | 1,072,899 (1%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Mates Sharon | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 22,590 | 0 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 70.11 per share. | 23 Feb 2024 | 12,462 | 1,050,309 (1%) | 0% | 70.1 | 873,711 | Common Stock |
| Intra-Cellular Therapies Inc | Mates Sharon | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 69.45 per share. | 23 Feb 2024 | 9,528 | 1,062,771 (1%) | 0% | 69.5 | 661,720 | Common Stock |
| Intra-Cellular Therapies Inc | Mates Sharon | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 68.39 per share. | 23 Feb 2024 | 600 | 1,072,299 (1%) | 0% | 68.4 | 41,034 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 33,885 | 1,084,194 (1%) | 0% | 0 | Common Stock | |
| Intra-Cellular Therapies Inc | Mates Sharon | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 67.42 per share. | 01 Feb 2024 | 17,450 | 1,050,309 (1%) | 0% | 67.4 | 1,176,479 | Common Stock |
| Intra-Cellular Therapies Inc | Mates Sharon | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 66.70 per share. | 01 Feb 2024 | 16,435 | 1,067,759 (1%) | 0% | 66.7 | 1,096,215 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 75,361 | 124,639 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Mates Sharon | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.86 per share. | 16 Jan 2024 | 75,361 | 1,125,670 (1%) | 0% | 16.9 | 1,270,586 | Common Stock |
| Intra-Cellular Therapies Inc | Mates Sharon | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 67,917 | 8,638 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.86 per share. | 16 Jan 2024 | 67,917 | 1,118,226 (1%) | 0% | 16.9 | 1,145,081 | Common Stock |
| Intra-Cellular Therapies Inc | Mates Sharon | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 65.19 per share. | 16 Jan 2024 | 67,597 | 1,050,629 (1%) | 0% | 65.2 | 4,406,648 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 67.25 per share. | 16 Jan 2024 | 65,979 | 1,056,191 (1%) | 0% | 67.3 | 4,437,088 | Common Stock |
| Intra-Cellular Therapies Inc | Mates Sharon | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.86 per share. | 16 Jan 2024 | 48,084 | 1,098,393 (1%) | 0% | 16.9 | 810,696 | Common Stock |
| Intra-Cellular Therapies Inc | Mates Sharon | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 48,084 | 76,555 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 66.00 per share. | 16 Jan 2024 | 30,633 | 1,067,760 (1%) | 0% | 66 | 2,021,778 | Common Stock |
| Intra-Cellular Therapies Inc | Mates Sharon | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 66.66 per share. | 16 Jan 2024 | 17,451 | 1,050,309 (1%) | 0% | 66.7 | 1,163,284 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 67.76 per share. | 16 Jan 2024 | 5,882 | 1,050,309 (1%) | 0% | 67.8 | 398,564 | Common Stock |
| Intra-Cellular Therapies Inc | Mates Sharon | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 66.38 per share. | 16 Jan 2024 | 3,500 | 1,122,170 (1%) | 0% | 66.4 | 232,330 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 66.25 per share. | 16 Jan 2024 | 320 | 1,050,309 (1%) | 0% | 66.3 | 21,200 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 41,770 | 1,172,079 (1%) | 0% | 0 | Common Stock | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 43.28 per share. | 09 Mar 2023 | 34,965 | 1,137,114 (1%) | 0% | 43.3 | 1,513,285 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 20,565 | 1,150,874 (1%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 20,565 | 41,131 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 09 Mar 2023 | 20,000 | 1,150,309 (1%) | 0% | 3.3 | 65,200 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 20,000 | 0 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 45.06 per share. | 09 Mar 2023 | 19,153 | 1,131,721 (1%) | 0% | 45.1 | 863,034 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 42.51 per share. | 09 Mar 2023 | 6,805 | 1,130,309 (1%) | 0% | 42.5 | 289,281 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 44.08 per share. | 09 Mar 2023 | 1,412 | 1,130,309 (1%) | 0% | 44.1 | 62,241 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 122,137 | 122,137 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 23 Feb 2023 | 30,000 | 1,130,309 (1%) | 0% | 3.3 | 97,800 | Common Stock |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 30,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Sharon Mates | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 22,590 | 1,122,899 (1%) | 0% | - | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges